Plasmacytoid dendritic cell role in cutaneous malignancies

Journal of Dermatological Science

Volumn 83, Issue 1, 2016, Pages 3-9

  Saadeh, Dana ^a   Kurban, Mazen ^a   Abbas, Ossama ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Basal cell carcinoma; Imiquimod; Interferon; Melanoma; Plasmacytoid dendritic cells; Skin cancer; Squamous cell carcinoma

Indexed keywords

BLOOD DERIVED DENDRITIC CELL ANTIGEN 2; CD123 ANTIGEN; CD4 ANTIGEN; CELL ANTIGEN; HLA DR ANTIGEN; IMIQUIMOD; INTERFERON; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; CYTOKINE;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; B CELL LYMPHOMA; BASAL CELL CARCINOMA; CANCER CELL; CELL COMPARTMENTALIZATION; CELL FUNCTION; CELL MIGRATION; CELL POPULATION; CELL STRUCTURE; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; ENDOSOME; HUMAN; INNATE IMMUNITY; LYMPHOCYTE; MELANOMA; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NON MELANOMA SKIN CANCER; NONHUMAN; PLASMA CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SKIN LYMPHOMA; VIRUS RESISTANCE; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; PATHOLOGY; SKIN TUMOR;

ADAPTIVE IMMUNITY; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9;

EID: 84969627120     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.05.008     Document Type: Review

References (90)

1. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
2. Swiecki M., Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 2015, 15:471-485.
3. Charles J., Chaperot L., Salameire D., et al. Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur. J. Dermatol. 2010, 20:16-23.
4. Jegalian A.G., Facchetti F., Jaffe E.S. Plasmacytoid dendritic cells: physiologic roles and pathologic states. Adv. Anat. Pathol. 2009, 16:392-404.
5. Gilliet M., Cao W., Liu Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8:594-606.
6. Lombardi V.C., Khaiboullina S.F., Rizvanov A.A. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression. Eur. J. Clin. Invest. 2015, 45:1-8.
7. Zitvogel L., Galluzzi L., Kepp O., Smyth M.J., Kroemer G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 2015, 15:405-414.
8. Rizza P., Moretti F., Capone I., Belardelli F. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications. Cytokine Growth Factor Rev. 2015, 26:195-201.
9. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14:36-49.
10. Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234.
11. Abbas O., Hussein L., Kurban M., Kibbi A.G. Plasmacytoid dendritic cell involvement in the host response against keratoacanthoma. J. Am. Acad. Dermatol. 2014, 70:1142-1145.
12. Saadeh D., Kurban M., Kibbi A.G., Abbas O. Involvement of plasmacytoid dendritic cells in the immunological response against Orf infection. JAMA Dermatol. 2014, 150:1112-1113.
13. Sleiman R., Kurban M., Abbas O. Evaluation of the diagnostic value of plasmacytoid dendritic cells in differentiating the lymphocytic cicatricial alopecias. Dermatology 2015, 231:158-163.
14. Abou Rahal J., Kurban M., Kibbi A.G., Abbas O. Plasmacytoid dendritic cells in alopecia areata: missing link. J. Eur. Acad. Dermatol. Venereol. 2016, 30:119-123.
15. Demoulin S., Herfs M., Delvenne P., Hubert P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol. 2013, 93:343-352.
16. Onai N., Kurabayashi K., Hosoi-Amaike M., et al. A clonogenic progenitor with prominent plasmacytoid dendritic cell developmental potential. Immunity 2013, 38:943-957.
17. Sasaki I., Hoshino K., Sugiyama T., et al. Spi-B is critical for plasmacytoid dendritic cell function and development. Blood 2012, 120:4733-4743.
18. Naik S.H., O'Keeffe M., Proietto A., Shortman H.H., Wu L. CD8+, CD8-, and plasmacytoid dendritic cell generation in vitro using flt3 ligand. Methods Mol. Biol. 2010, 595:167-176.
19. Blom B., Ho S., Antonenko S., Liu Y.J. Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J. Exp. Med. 2000, 192:1785-1796.
20. Nagasawa M., Schmidlin H., Hazekamp M.G., Schotte R., Blom B. Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B. Eur. J. Immunol. 2008, 38:2389-2400.
21. Shortman K., Sathe P., Vremec D., Naik S., O'Keeffe M. Plasmacytoid dendritic cell development. Adv. Immunol. 2013, 120:105-126.
22. Jiménez-Dalmaroni M.J., Gerswhin M.E., Adamopoulos I.E. The critical role of toll-like receptors - From microbial recognition to autoimmunity: a comprehensive review. Autoimmun. Rev. 2015, (August). pii: S1568-9972(15)00184-6. 10.1016/j.autrev.2015.08.009.
23. Bao M., Liu Y.J. Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell. 2013, 4:40-52.
24. Izaguirre A., Barnes B.J., Amrute S., et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 2003, 74:1125-1138.
25. Young L.J., Wilson N.S., Schnorrer P., et al. Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat. Immunol. 2008, 9:1244-1252.
26. Guillerme J.B., Boisgerault N., Roulois D., et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin. Cancer Res. 2013, 19:1147-1158.
27. Tel J., Schreibelt G., Sittig S.P., et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2013, 121:459-467.
28. Tel J., Sittig S.P., Blom R.A., et al. Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J. Immunol. 2013, 191:5005-5012.
29. Dzionek A., Inagaki Y., Okawa K., et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum. Immunol. 2002, 63:1133-1148.
30. Cao W. Molecular characterization of human plasmacytoid dendritic cells. J. Clin. Immunol. 2009, 29:257-264.
31. Salio M., Cella M., Vermi W., et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol. 2003, 33:1052-1062.
32. Wenzel J., Bekisch B., Uerlich M., Haller O., Bieber T., Tuting T. Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin. Pathol. 2005, 124:37-48.
33. Bratke K., Nielsen J., Manig F., et al. Functional expression of granzyme B in human plasmacytoid dendritic cells: a role in allergic inflammation. Clin. Exp. Allergy 2010, 40:1015-1024.
34. Tel J., Smits E.L., Anguille S., Joshi R.N., Figdor C.G., de Vries I.J. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 2012, 120:3936-3944.
35. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 2007, 204:1441-1451.
36. Kalb M.L., Glaser A., Stary G., Koszik F., Stingl G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol. 2012, 188:1583-1591.
37. Drobits B., Holcmann M., Amberg N., et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 2012, 122:575-585.
38. Labidi-Galy S.I., Treilleux I., Goddard-Leon S., et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012, 1:380-382.
39. Treilleux I., Blay J.Y., Bendriss-Vermare N., et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 2004, 10:7466-7474.
40. Charles J., Di Domizio J., Salameire D., et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J. Invest. Dermatol. 2010, 130:1646-1656.
41. Vermi W., Bonecchi R., Facchetti F., et al. Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 2003, 200:255-268.
42. Gerlini G., Urso C., Mariotti G., et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol. 2007, 125:184-193.
43. Jensen T.O., Schmidt H., Moller H.J., et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012, 118:2476-2485.
44. Aspord C., Leccia M.T., Charles J., Plumas J. Plasmacytoid dendritic cells support melanoma progression by promoting Th2 and regulatory immunity through OX40L and ICOSL. Cancer Immunol Res. 2013, 1:402-415.
45. Matsui T., Connolly J.E., Michnevitz M., et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J. Immunol. 2009, 182:6815-6823.
46. Chaperot L., Blum A., Manches O., et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 2006, 176:248-255.
47. Rothenfusser S., Hornung V., Ayyoub M., et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8 T-cell responses in vitro. Blood 2004, 103:2162-2169.
48. Liu C., Lou Y., Lizee G., et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J. Clin. Invest. 2008, 118:1165-1175.
49. Furumoto K., Soares L., Engleman E.G., Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 2004, 113:774-783.
50. Speiser D.E., Lienard D., Rufer N., et al. Rapid and strong human CD8 T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115:739-746.
51. Pashenkov M., Goess G., Wagner C., et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 2006, 24:5716-5724.
52. Molenkamp B.G., Sluijter B.J., van Leeuwen P.A., et al. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8T-cell reactivity in melanoma patients. Clin. Cancer Res. 2008, 14:4532-4542.
53. Ito T., Yang M., Wang Y.H., et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 2007, 204:105-115.
54. Ito T., Hanabuchi S., Wang Y.H., et al. Two functional subsets of FOXP3 regulatory T cells in human thymus and periphery. Immunity 2008, 28:870-880.
55. Gilliet M., Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J. Exp. Med. 2002, 195:695-704.
56. Conrad C., Gregorio J., Wang Y.H., et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3() T-regulatory cells. Cancer Res. 2012, 72:5240-5249.
57. Martin-Orozco N., Li Y., Wang Y., et al. Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res. 2010, 70:9581-9590.
58. Sharma M.D., Baban B., Chandler P., et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 2007, 117:2570-2582.
59. Chevolet I., Speeckaert R., Haspeslagh M., et al. Peri-tumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. Br. J. Dermatol. 2014, 171:987-995. (9).
60. Speeckaert R., Vermaelen K., van Geel N., et al. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. Eur. J. Cancer 2012, 48:2004-2011.
61. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14:36-49.
62. Haller O., Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J. Interferon Cytokine Res. 2011, 31:79-87.
63. Bekeredjian-Ding I., Schafer M., Hartmann E., et al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology 2009, 128:439-450.
64. Hack K., Reilly L., Proby C., Fleming C., Leigh I., Foerster J. Wnt5a inhibits the CpG oligodeoxynucleotide-triggered activation of human plasmacytoid dendritic cells. Clin. Exp. Dermatol. 2012, 37:557-561.
65. Cao W., Bover L. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol. Rev. 2010, 234:163-176.
66. Camisaschi C., De Filippo A., Beretta V., et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3. J. Invest. Dermatol. 2014, 134:1893-1902.
67. Mühleisen B., Petrov I., Gächter T., et al. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology 2009, 55:67-76.
68. Freeman A., Bridge J.A., Maruthayanar P., et al. Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage. PLoS One 2014, 9:e110928.
69. Ogawa Y., Kawamura T., Matsuzawa T., Aoki R., Shimada S. Recruitment of plasmacytoid dendritic cells to skin regulates treatment responsiveness of actinic keratosis to imiquimod. J. Dermatol. Sci. 2014, 76:67-69.
70. Urosevic M., Dummer R., Conrad C., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl. Cancer Inst. 2005, 97:1143-1153.
71. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., Stingl G. Tumouricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 2007, 204:1441-1451.
72. Kaporis H.G., Guttman-Yassky E., Lowes M.A., et al. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J. Invest. Dermatol. 2007, 127:2391-2398.
73. Dowlatshahi M., Huang V., Gehad A.E., et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J. Invest. Dermatol. 2013, 133:1879-1889.
74. Wei S., Kryczek I., Zou L., et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005, 65:5020-5026.
75. Baecher-Allan C., Wolf E., Hafler D.A. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 2006, 176:4622-4631.
76. Kutzner H., Kerl H., Pfaltz M.C., Kempf W. CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: diagnostic and pathogenetic implications. Am. J. Surg. Pathol. 2009, 33:1307-1313.
77. Kempf W., Kerl H., Kutzner H. CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: a crucial role and a new lymphoma paradigm. Am. J. Dermatopathol. 2010, 32:194-196.
78. Christie L.J., MacKenzie C., Palmer T.J., Baker L., Goodlad J.R. Type and maturational status of dendritic cells in cutaneous B cell lymphoproliferative disorders. Histopathology 2011, 59:421-432.
79. Schlapbach C., Ochsenbein A., Kaelin U., et al. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 2010, 62:995-1004.
80. Schwingshackl P., Obermoser G., Nguyen V.A., Fritsch P., Sepp N., Romani N. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Acta Derm. Venereol. 2012, 92:269-275.
81. Dargent J.L., Henne S., Pranger D., et al. Tumor-forming plasmacytoid dendritic cells associated with myeloid neoplasms. Report of a peculiar case with histopathologic features masquerading as lupus erythematosus. J. Cutan. Pathol. 2015, Oct. 10.1111/cup.12639.
82. Julia F., Dalle S., Duru G., et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am. J. Surg. Pathol. 2014, 38:673-680.
83. Shi Y., Wang E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. Arch. Pathol. Lab. Med. 2014, 138:564-569.
84. Miller R.L., Gerster J.F., Owens M.L., Slade H.B., Tomai M.A. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. J. Immunopharmacol. 1999, 21:1-14.
85. Hadley G., Derry S., Moore R.A. Imiquimod for actinic keratosis: systematic review and meta-analysis. J. Invest. Dermatol. 2006, 126:1251-1255.
86. Stockfleth E. Lmax and imiquimod 3.75%: the new standard in AK management. J. Eur. Acad. Dermatol. Venereol. 2015, 29:9-14.
87. Mackenzie-Wood A., Kossard S., de Launey J., Wilkinson B., Owens M.L. Imiquimod 5% cream in the treatment of Bowen's disease. J. Am. Acad. Dermatol. 2001, 44:462-470.
88. Patel G.K., Goodwin R., Chawla M., et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 2006, 54:1025-1032.
89. Ahmed I., Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br. J. Dermatol. 2000, 143:843-845.
90. Kamin A., Eigentler T.K., Radny P., Bauer J., Weide B., Garbe C. Imiquimod in the treatment of extensive recurrent lentigo maligna. J. Am. Acad. Dermatol. 2005, 52:51-52.